NASDAQ:TCBP - Nasdaq - US87807D6085 - ADR - Currency: USD
0.5
-1.04 (-67.53%)
The current stock price of TCBP is 0.5 USD. In the past month the price decreased by -80%. In the past year, price decreased by -99.79%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.39 | 329.14B | ||
AMGN | AMGEN INC | 14.17 | 150.99B | ||
GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
NTRA | NATERA INC | N/A | 20.79B | ||
BIIB | BIOGEN INC | 7.22 | 17.39B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 41 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. The company is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.
TC BIOPHARM HOLDINGS PLC-ADR
Maxim 1, 2 Parklands Way, Holytown
Motherwell GB
Employees: 41
Company Website: https://www.tcbiopharm.com
Investor Relations: https://www.tcbiopharm.com/news/press-releases
Phone: 441414337557
The current stock price of TCBP is 0.5 USD. The price decreased by -67.53% in the last trading session.
The exchange symbol of TC BIOPHARM HOLDINGS PLC-ADR is TCBP and it is listed on the Nasdaq exchange.
TCBP stock is listed on the Nasdaq exchange.
7 analysts have analysed TCBP and the average price target is 48.96 USD. This implies a price increase of 9692% is expected in the next year compared to the current price of 0.5. Check the TC BIOPHARM HOLDINGS PLC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TC BIOPHARM HOLDINGS PLC-ADR (TCBP) has a market capitalization of 5.13M USD. This makes TCBP a Nano Cap stock.
TC BIOPHARM HOLDINGS PLC-ADR (TCBP) currently has 41 employees.
The Revenue of TC BIOPHARM HOLDINGS PLC-ADR (TCBP) is expected to decline by -100% in the next year. Check the estimates tab for more information on the TCBP EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TCBP does not pay a dividend.
TC BIOPHARM HOLDINGS PLC-ADR (TCBP) will report earnings on 2022-12-13, before the market open.
TC BIOPHARM HOLDINGS PLC-ADR (TCBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.21).
The outstanding short interest for TC BIOPHARM HOLDINGS PLC-ADR (TCBP) is 0.41% of its float. Check the ownership tab for more information on the TCBP short interest.
ChartMill assigns a fundamental rating of 1 / 10 to TCBP. Both the profitability and financial health of TCBP have multiple concerns.
Over the last trailing twelve months TCBP reported a non-GAAP Earnings per Share(EPS) of -4.21. The EPS decreased by -27216.05% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -71.77% | ||
ROE | -293.88% | ||
Debt/Equity | 1.07 |
ChartMill assigns a Buy % Consensus number of 83% to TCBP. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 96.52% and a revenue growth -100% for TCBP